Last reviewed · How we verify
Placebo with 0.09% menthol gel
Placebo with 0.09% menthol gel is a Topical analgesic/counterirritant Small molecule drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Topical pain relief (likely musculoskeletal or localized pain indication in Phase 3 trial).
Menthol provides topical cooling and mild analgesic sensation through activation of TRPM8 cold-sensitive receptors on the skin.
Menthol provides topical cooling and mild analgesic sensation through activation of TRPM8 cold-sensitive receptors on the skin. Used for Topical pain relief (likely musculoskeletal or localized pain indication in Phase 3 trial).
At a glance
| Generic name | Placebo with 0.09% menthol gel |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Topical analgesic/counterirritant |
| Target | TRPM8 (transient receptor potential melastatin 8) |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | Phase 3 |
Mechanism of action
Menthol is a naturally occurring compound that binds to transient receptor potential melastatin 8 (TRPM8) channels, creating a cooling sensation and potentially modulating pain perception at the application site. This topical effect may provide symptomatic relief through counter-irritation and desensitization of nociceptors. The placebo formulation serves as a control in clinical trials to assess the true efficacy of menthol versus inert vehicle.
Approved indications
- Topical pain relief (likely musculoskeletal or localized pain indication in Phase 3 trial)
Common side effects
- Local skin irritation
- Burning or stinging at application site
- Erythema
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo with 0.09% menthol gel CI brief — competitive landscape report
- Placebo with 0.09% menthol gel updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Placebo with 0.09% menthol gel
What is Placebo with 0.09% menthol gel?
How does Placebo with 0.09% menthol gel work?
What is Placebo with 0.09% menthol gel used for?
Who makes Placebo with 0.09% menthol gel?
What drug class is Placebo with 0.09% menthol gel in?
What development phase is Placebo with 0.09% menthol gel in?
What are the side effects of Placebo with 0.09% menthol gel?
What does Placebo with 0.09% menthol gel target?
Related
- Drug class: All Topical analgesic/counterirritant drugs
- Target: All drugs targeting TRPM8 (transient receptor potential melastatin 8)
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Pain Management
- Indication: Drugs for Topical pain relief (likely musculoskeletal or localized pain indication in Phase 3 trial)
- Compare: Placebo with 0.09% menthol gel vs similar drugs
- Pricing: Placebo with 0.09% menthol gel cost, discount & access